Product image of Natrijev Metamizolat Krka (Metamizole Sodium Monohydrate) supplied by GNH India

Natrijev Metamizolat Krka

Active Ingredient:
Metamizole Sodium Monohydrate
Origin:
EU

Natrijev Metamizolat Krka (Metamizole Sodium Monohydrate)

Metamizole sodium, the active ingredient in Natrijev Metamizolat Krka, is a pyrazolone derivative presented as a sterile injectable solution for intramuscular or intravenous use. It is employed to relieve moderate to severe pain and to reduce high fever in adult patients.
GNH India supplies Natrijev Metamizolat Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Krka, D.D., Novo Mesto

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metamizole sodium is indicated for conditions where strong analgesia or antipyresis is required.

  • Moderate to severe pain: provides rapid pain relief when weaker analgesics are insufficient.
  • Post‑operative pain: helps control surgical pain during the immediate recovery period.
  • Colic: reduces visceral pain associated with gastrointestinal spasm.
  • High fever: lowers body temperature when antipyretic therapy is needed.

How It Works

  • Metamizole sodium acts as a non‑opioid analgesic by inhibiting cyclo‑oxygenase enzymes, thereby reducing prostaglandin synthesis. The decreased prostaglandin levels diminish peripheral sensitisation and central pain transmission. Additionally, the drug modulates central pain pathways, contributing to its antipyretic effect through hypothalamic temperature regulation.

Side Effects

Metamizole sodium may cause a range of adverse reactions, from mild to severe.

Common Side Effects

  • Injection site pain or erythema: local discomfort at the administration site.
  • Nausea or vomiting: gastrointestinal upset following dosing.
  • Dizziness or light‑headedness: transient vertigo or feeling faint.
  • Transient hypotension: temporary drop in blood pressure after rapid IV administration.

Serious or Rare Side Effects

  • Agranulocytosis: severe reduction of neutrophils, increasing infection risk.
  • Severe skin reactions (e.g., Stevens‑Johnson syndrome): extensive rash or mucosal involvement.
  • Anaphylactic reaction: sudden, life‑threatening allergic response.
  • Hepatic enzyme elevation: abnormal liver function tests indicating possible liver injury.

Precautions & Warnings

Before initiating therapy, clinicians should assess patient suitability and monitor for adverse events.

  • Baseline blood count: obtain complete blood count to detect pre‑existing leukopenia.
  • Infection monitoring: watch for signs of infection, especially if agranulocytosis develops.
  • Hypersensitivity: avoid in patients with known allergy to pyrazolones or Metamizole.
  • Renal/hepatic impairment: use with caution and consider dose adjustment.
  • Pregnancy: limit use to situations where benefit outweighs potential risk.
  • Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Metamizole sodium can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

  • Other myelotoxic agents (e.g., chemotherapy): may compound risk of agranulocytosis.
  • Anticoagulants (e.g., warfarin): can enhance bleeding tendency.
  • Concurrent pyrazolone derivatives: increase risk of severe hematologic toxicity.

Moderate Interactions (Monitor Closely)

  • ACE inhibitors or diuretics: may potentiate hypotensive effects.
  • NSAIDs: additive renal stress and gastrointestinal irritation.
  • Alcohol: can exacerbate dizziness and hypotension.

Frequently Asked Questions

Natrijev Metamizolat Krka, containing Metamizole sodium, is prescribed for moderate to severe acute pain, post‑operative pain, colic, and high fever when other analgesics or antipyretics are insufficient. It is administered by a healthcare professional via intramuscular or intravenous injection.

Metamizole sodium inhibits cyclo‑oxygenase enzymes, reducing prostaglandin production. Lower prostaglandin levels decrease peripheral sensitisation and central pain signalling, providing analgesia. The drug also acts on the hypothalamic thermoregulatory centre, lowering elevated body temperature.

The specific dose and frequency are determined by the prescribing clinician based on the patient’s age, weight, severity of pain or fever, and clinical setting. Dosing information is provided on the prescription and should not be altered without medical guidance.

Safety data for Metamizole sodium in pregnancy and lactation are limited. It should only be used when the potential benefit justifies the possible risk to the fetus or infant, and only under direct medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Metamizole provides strong analgesia and antipyresis without the gastrointestinal ulcer risk associated with many NSAIDs and without the respiratory depression seen with opioids. However, it carries a unique risk of agranulocytosis, which is not typical for NSAIDs or opioids, so monitoring blood counts is essential.

The product should be stored at temperatures below 25 °C, protected from moisture and direct sunlight. Keep the vial in its original packaging until use, and discard any solution that appears discoloured or contains particles.

Administration is performed by a qualified healthcare professional. The sterile solution is injected either intramuscularly or intravenously, depending on the clinical situation and physician’s judgment. Intravenous infusion should be given slowly to minimise hypotensive reactions.

The most serious adverse events are agranulocytosis, which can lead to severe infections, and rare but life‑threatening allergic reactions such as anaphylaxis or severe skin disorders like Stevens‑Johnson syndrome. Immediate medical attention is required if these symptoms appear.

Patients with known hypersensitivity to Metamizole or other pyrazolones, those with existing severe leukopenia or agranulocytosis, and individuals for whom safer alternatives are available should avoid this medication. Use is also contraindicated in patients with uncontrolled hypotension.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.